The EMA is seeking industry comment on product-specific guidance on bioequivalence studies for asenapine, prasugrel, sitagliptin and zonisamide. Besides being required for generic drugs, the studies may be necessary to support applications for marketing authorization variations, fixed-dose combinations, indication extensions and hybrid applications.